Nov. 17, 2023

HippoScreen's Stress EEG Assessment (SEA) System obtained TFDA Approval

HippoScreen has received Taiwan Food and Drug Administration (TFDA) Class II clearance for the Stress EEG Assessment (SEA) System as Software as a Medical Device (SaMD).  It is the first SaMD to be used as assistance in the diagnosis of Major Depression Disorder.

This marks a siginificant step of the company. We look forward to applying SEA technology to screening more people and help raise public mental health.